vs
FIRST UNITED CORP（FUNC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是FIRST UNITED CORP的1.3倍（$30.3M vs $23.2M），FIRST UNITED CORP净利率更高（24.9% vs -221.3%，领先246.2%），REGENXBIO Inc.同比增速更快（43.0% vs 11.9%），FIRST UNITED CORP自由现金流更多（$15.4M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.5%）
联合啤酒控股有限公司（又称UB集团）是喜力集团旗下的印度子公司，总部位于卡纳塔克邦班加罗尔的UB城。公司核心业务涵盖酒类饮品生产及多领域投资，是印度最大的啤酒生产商，主打以翠鸟为品牌的啤酒产品，同时拥有多款其他酒类品牌。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FUNC vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.2M
营收增速更快
RGNX
高出31.1%
11.9%
净利率更高
FUNC
高出246.2%
-221.3%
自由现金流更多
FUNC
多$68.2M
$-52.8M
两年增速更快
RGNX
近两年复合增速
11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.2M | $30.3M |
| 净利润 | $5.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 32.9% | -190.0% |
| 净利率 | 24.9% | -221.3% |
| 营收同比 | 11.9% | 43.0% |
| 净利润同比 | -6.6% | -31.2% |
| 每股收益（稀释后） | $0.89 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FUNCRGNX
| Q4 25 | $23.2M | $30.3M | ||
| Q3 25 | $22.7M | $29.7M | ||
| Q2 25 | $21.8M | $21.4M | ||
| Q1 25 | $20.9M | $89.0M | ||
| Q4 24 | $20.8M | $21.2M | ||
| Q3 24 | $20.3M | $24.2M | ||
| Q2 24 | $20.1M | $22.3M | ||
| Q1 24 | $18.7M | $15.6M |
净利润FUNCRGNX
| Q4 25 | $5.8M | $-67.1M | ||
| Q3 25 | $6.9M | $-61.9M | ||
| Q2 25 | $6.0M | $-70.9M | ||
| Q1 25 | $5.8M | $6.1M | ||
| Q4 24 | $6.2M | $-51.2M | ||
| Q3 24 | $5.8M | $-59.6M | ||
| Q2 24 | $4.9M | $-53.0M | ||
| Q1 24 | $3.7M | $-63.3M |
毛利率FUNCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FUNCRGNX
| Q4 25 | 32.9% | -190.0% | ||
| Q3 25 | 40.6% | -176.3% | ||
| Q2 25 | 36.5% | -296.3% | ||
| Q1 25 | 36.8% | 13.6% | ||
| Q4 24 | 39.2% | -242.1% | ||
| Q3 24 | 38.0% | -256.6% | ||
| Q2 24 | 32.5% | -251.3% | ||
| Q1 24 | 26.0% | -408.8% |
净利率FUNCRGNX
| Q4 25 | 24.9% | -221.3% | ||
| Q3 25 | 30.6% | -208.3% | ||
| Q2 25 | 27.5% | -331.8% | ||
| Q1 25 | 27.7% | 6.8% | ||
| Q4 24 | 29.8% | -241.3% | ||
| Q3 24 | 28.5% | -246.3% | ||
| Q2 24 | 24.5% | -237.7% | ||
| Q1 24 | 19.8% | -405.4% |
每股收益（稀释后）FUNCRGNX
| Q4 25 | $0.89 | $-1.30 | ||
| Q3 25 | $1.07 | $-1.20 | ||
| Q2 25 | $0.92 | $-1.38 | ||
| Q1 25 | $0.89 | $0.12 | ||
| Q4 24 | $0.95 | $-0.99 | ||
| Q3 24 | $0.89 | $-1.17 | ||
| Q2 24 | $0.75 | $-1.05 | ||
| Q1 24 | $0.56 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $131.6M | $230.1M |
| 总债务越低越好 | $95.9M | — |
| 股东权益账面价值 | $203.6M | $102.7M |
| 总资产 | $2.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.47× | — |
8季度趋势，按日历期对齐
现金及短期投资FUNCRGNX
| Q4 25 | $131.6M | $230.1M | ||
| Q3 25 | $95.2M | $274.2M | ||
| Q2 25 | $79.1M | $323.3M | ||
| Q1 25 | $84.4M | $267.9M | ||
| Q4 24 | $78.3M | $234.7M | ||
| Q3 24 | $62.4M | $255.5M | ||
| Q2 24 | $45.1M | $290.4M | ||
| Q1 24 | $86.9M | $338.7M |
总债务FUNCRGNX
| Q4 25 | $95.9M | — | ||
| Q3 25 | $95.9M | — | ||
| Q2 25 | $120.9M | — | ||
| Q1 25 | $120.9M | — | ||
| Q4 24 | $120.9M | — | ||
| Q3 24 | $120.9M | — | ||
| Q2 24 | $70.9M | — | ||
| Q1 24 | $70.9M | — |
股东权益FUNCRGNX
| Q4 25 | $203.6M | $102.7M | ||
| Q3 25 | $199.1M | $161.5M | ||
| Q2 25 | $191.1M | $213.7M | ||
| Q1 25 | $183.7M | $274.2M | ||
| Q4 24 | $179.3M | $259.7M | ||
| Q3 24 | $174.0M | $301.4M | ||
| Q2 24 | $164.2M | $348.3M | ||
| Q1 24 | $165.5M | $390.7M |
总资产FUNCRGNX
| Q4 25 | $2.1B | $453.0M | ||
| Q3 25 | $2.0B | $525.2M | ||
| Q2 25 | $2.0B | $581.0M | ||
| Q1 25 | $2.0B | $490.9M | ||
| Q4 24 | $2.0B | $466.0M | ||
| Q3 24 | $1.9B | $519.1M | ||
| Q2 24 | $1.9B | $569.4M | ||
| Q1 24 | $1.9B | $629.2M |
负债/权益比FUNCRGNX
| Q4 25 | 0.47× | — | ||
| Q3 25 | 0.48× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.67× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 0.43× | — | ||
| Q1 24 | 0.43× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $15.4M | $-52.8M |
| 自由现金流率自由现金流/营收 | 66.3% | -174.0% |
| 资本支出强度资本支出/营收 | 17.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 3.35× | — |
| 过去12个月自由现金流最近4个季度 | $22.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FUNCRGNX
| Q4 25 | $19.4M | $-52.3M | ||
| Q3 25 | $1.5M | $-56.0M | ||
| Q2 25 | $995.0K | $-49.3M | ||
| Q1 25 | $7.0M | $33.6M | ||
| Q4 24 | $22.3M | $-31.6M | ||
| Q3 24 | $2.3M | $-40.5M | ||
| Q2 24 | $7.2M | $-45.5M | ||
| Q1 24 | $3.6M | $-55.5M |
自由现金流FUNCRGNX
| Q4 25 | $15.4M | $-52.8M | ||
| Q3 25 | $168.0K | $-56.5M | ||
| Q2 25 | $706.0K | $-49.7M | ||
| Q1 25 | $6.4M | $32.6M | ||
| Q4 24 | $20.4M | $-32.7M | ||
| Q3 24 | $588.0K | $-40.9M | ||
| Q2 24 | $7.0M | $-46.0M | ||
| Q1 24 | $3.5M | $-56.0M |
自由现金流率FUNCRGNX
| Q4 25 | 66.3% | -174.0% | ||
| Q3 25 | 0.7% | -189.9% | ||
| Q2 25 | 3.2% | -232.8% | ||
| Q1 25 | 30.5% | 36.6% | ||
| Q4 24 | 98.1% | -154.2% | ||
| Q3 24 | 2.9% | -168.9% | ||
| Q2 24 | 35.1% | -206.2% | ||
| Q1 24 | 18.9% | -358.5% |
资本支出强度FUNCRGNX
| Q4 25 | 17.1% | 1.7% | ||
| Q3 25 | 5.9% | 1.7% | ||
| Q2 25 | 1.3% | 1.8% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | 9.3% | 5.1% | ||
| Q3 24 | 8.4% | 1.3% | ||
| Q2 24 | 0.6% | 2.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率FUNCRGNX
| Q4 25 | 3.35× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.17× | — | ||
| Q1 25 | 1.20× | 5.53× | ||
| Q4 24 | 3.60× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 1.46× | — | ||
| Q1 24 | 0.97× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FUNC
| Trust Department | $9.8M | 42% |
| Other | $5.6M | 24% |
| Debit Card Income | $4.1M | 17% |
| Service Charges | $2.3M | 10% |
| Brokerage Commissions | $1.4M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
